L. Jayaraman

发表

Covalent and noncovalent modifiers of the p53 protein

C. Prives, L. Jayaraman, 1999, Cellular and Molecular Life Sciences CMLS.

High mobility group protein-1 (HMG-1) is a unique activator of p53.

C. Prives, M. Bustin, L. Jayaraman, 1998, Genes & development.

Functional dissection of p53 tumor suppressor protein.

C. Prives, L. Jayaraman, E. Freulich, 1997, Methods in enzymology.

Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus

C. Prives, L. Jayaraman, 1995, Cell.

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

X. Chen, C. Prives, L. Ko, 1996, Genes & development.

Distinct Oligomeric States of SMAD Proteins in the Transforming Growth Factor-β Pathway*

J. Massagué, L. Jayaraman, Lata Jayaraman, 2000, The Journal of Biological Chemistry.

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1).

S. Pang, M. Poss, L. Jayaraman, 2008, Bioorganic & medicinal chemistry letters.

Identification of redox/repair protein Ref-1 as a potent activator of p53.

T. Curran, C. Prives, L. Jayaraman, 1997, Genes & development.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Crystal Structure of a Smad MH1 Domain Bound to DNA Insights on DNA Binding in TGF-β Signaling

Yigong Shi, J. Massagué, Yigong Shi, 1998, Cell.

Physical and Functional Interaction of SMADs and p300/CBP*

J. Massagué, L. Jayaraman, C. Pouponnot, 1998, The Journal of Biological Chemistry.

CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.

Andrew Z. Wang, J. Tepper, S. Eliasof, 2017, Cancer research.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

R. Kerbel, S. Eliasof, Christina R. Lee, 2016, Cancer research.

The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer.

J. Tokarski, A. Fura, L. Jayaraman, 2022, Bioorganic & medicinal chemistry letters.

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

A. Doweyko, G. Trainor, A. Fura, 2016, ACS medicinal chemistry letters.

p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner

X. Chen, C. Prives, L. Ko, 1997, Molecular and cellular biology.

An electrophoretic mobility shift assay for the identification and kinetic analysis of acetyl transferase inhibitors.

L. Jayaraman, Y. Blat, D. Pedicord, 2010, Analytical biochemistry.

Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.

K. Kish, H. Klei, D. Xie, 2011, The Biochemical journal.

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit

Raquel S. Sevilla, A. Kral, R. Kennan, 2017, Scientific Reports.

Complex formation between p53 and replication protein A inhibits the sequence-specific DNA binding of p53 and is regulated by single-stranded DNA

C. Prives, L. Jayaraman, S. Miller, 1997, Molecular and cellular biology.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

D. Heitjan, A. Nixon, S. Eliasof, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Dissecting Therapeutic Resistance to ERK Inhibition

L. Zawel, S. Fawell, L. Jayaraman, 2016, Molecular Cancer Therapeutics.

Abstract B063: Leveraging gut microbiota networks to impact tumor immunotherapy

J. Wortman, M. Henn, L. Jayaraman, 2019, Microbiome and Metabolism.

Synthesis and Biological Evaluation of Biaryl Alkyl Ethers as Inhibitors of IDO1.

Xin Li, J. Hunt, L. Jayaraman, 2023, Bioorganic & medicinal chemistry letters.

DNA-binding properties of the p53 tumor suppressor protein.

J. Bargonetti, C. Prives, P. Friedlander, 1994, Cold Spring Harbor symposia on quantitative biology.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

R. Kerbel, S. Eliasof, Christina R. Lee, 2016, Cancer research.

Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.

K. Kish, H. Klei, D. Xie, 2011, The Biochemical journal.